161 related articles for article (PubMed ID: 31239542)
1. Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
Lecavalier-Barsoum M; Chaudary N; Han K; Pintilie M; Hill RP; Milosevic M
Br J Cancer; 2019 Jul; 121(3):249-256. PubMed ID: 31239542
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.
Chaudary N; Pintilie M; Jelveh S; Lindsay P; Hill RP; Milosevic M
Clin Cancer Res; 2017 Mar; 23(5):1242-1249. PubMed ID: 27697997
[No Abstract] [Full Text] [Related]
3. The Oral CXCR4 Inhibitor X4-136 Improves Tumor Control and Reduces Toxicity in Cervical Cancer Treated With Radiation Therapy and Concurrent Chemotherapy.
Chaudary N; Hill RP; Stulik L; Milosevic M
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1317-1324. PubMed ID: 33771702
[TBL] [Abstract][Full Text] [Related]
4. Targeting the CXCL12/CXCR4 pathway and myeloid cells to improve radiation treatment of locally advanced cervical cancer.
Lecavalier-Barsoum M; Chaudary N; Han K; Koritzinsky M; Hill R; Milosevic M
Int J Cancer; 2018 Sep; 143(5):1017-1028. PubMed ID: 29417588
[TBL] [Abstract][Full Text] [Related]
5. Impact of CXCR4/CXCL12 Blockade on Normal Plasma Cells In Vivo.
Moore N; Moreno Gonzales M; Bonner K; Smith B; Park W; Stegall M
Am J Transplant; 2017 Jun; 17(6):1663-1669. PubMed ID: 28235241
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
7. The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling.
Ping YF; Yao XH; Jiang JY; Zhao LT; Yu SC; Jiang T; Lin MC; Chen JH; Wang B; Zhang R; Cui YH; Qian C; Wang Jm; Bian XW
J Pathol; 2011 Jul; 224(3):344-54. PubMed ID: 21618540
[TBL] [Abstract][Full Text] [Related]
8. Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
Chen FH; Fu SY; Yang YC; Wang CC; Chiang CS; Hong JH
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):777-84. PubMed ID: 23601898
[TBL] [Abstract][Full Text] [Related]
9. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
10. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
11. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
12. Hedgehog inhibition enhances efficacy of radiation and cisplatin in orthotopic cervical cancer xenografts.
Chaudary N; Pintilie M; Hedley D; Hill RP; Milosevic M; Mackay H
Br J Cancer; 2017 Jan; 116(1):50-57. PubMed ID: 27875522
[TBL] [Abstract][Full Text] [Related]
13. Plerixafor, a CXCR4 antagonist, mitigates skin radiation-induced injury in mice.
Kim JH; Kolozsvary A; Jenrow KA; Brown SL
Radiat Res; 2012 Sep; 178(3):202-6. PubMed ID: 22799631
[TBL] [Abstract][Full Text] [Related]
14. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
Green MM; Chao N; Chhabra S; Corbet K; Gasparetto C; Horwitz A; Li Z; Venkata JK; Long G; Mims A; Rizzieri D; Sarantopoulos S; Stuart R; Sung AD; Sullivan KM; Costa L; Horwitz M; Kang Y
J Hematol Oncol; 2016 Aug; 9(1):71. PubMed ID: 27535663
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor: a peripheral blood stem cell mobilizer.
Kessans MR; Gatesman ML; Kockler DR
Pharmacotherapy; 2010 May; 30(5):485-92. PubMed ID: 20411999
[TBL] [Abstract][Full Text] [Related]
17. Targeting the CXCL12/CXCR4 pathway to reduce radiation treatment side effects.
Chaudary N; Hill RP; Milosevic M
Radiother Oncol; 2024 May; 194():110194. PubMed ID: 38447871
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological targeting of CXCL12/CXCR4 signaling in prostate cancer bone metastasis.
Conley-LaComb MK; Semaan L; Singareddy R; Li Y; Heath EI; Kim S; Cher ML; Chinni SR
Mol Cancer; 2016 Nov; 15(1):68. PubMed ID: 27809841
[TBL] [Abstract][Full Text] [Related]
19. Combining SDF-1/CXCR4 antagonism and chemotherapy in relapsed acute myeloid leukemia.
Fierro FA; Brenner S; Oelschlaegel U; Jacobi A; Knoth H; Ehninger G; Illmer T; Bornhäuser M
Leukemia; 2009 Feb; 23(2):393-6. PubMed ID: 18615106
[No Abstract] [Full Text] [Related]
20. Experimental study of the inhibition effect of CXCL12/CXCR4 in malignant pleural mesothelioma.
Li J; Li T; Li S; Xie L; Yang YL; Lin Q; Kadoch O; Li H; Hou S; Xu Z
J Investig Med; 2019 Feb; 67(2):338-345. PubMed ID: 30367010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
